Detalhe da pesquisa
1.
Phase I study of OPB-51602, an oral inhibitor of signal transducer and activator of transcription 3, in patients with relapsed/refractory hematological malignancies.
Cancer Sci;
106(7): 896-901, 2015 Jul.
Artigo
em Inglês
| MEDLINE
| ID: mdl-25912076